Sign up
Pharma Capital

WideCells Group resumes trading - looks to close fundraise by end of month

Joao Andrade and David Bridgland from WideCells Group PLC (LON:WDC) discuss the recent suspension of shares due to a delay in the publication of their full year results.

This week the company updated shareholders reconfirming that it's received commitments for its shares placing of at least £1.8mln, and anticipates being able to close the fundraiser before the end of the month.

The sum expected to be raised is in excess of the £1.5mln it requires to continue as a going concern.

WideCells also announced that the Live Market Bookbuild, which commenced on 10 May 2018, has now closed having received commitments to raise a further £513,000.

 

View full WDC profile View Profile
View All

© biotech Capital 2018

Biotech Capital, a subsidiary of Proactive Investors, acts as the vanguard for listed biotech companies to interact with institutional and highly capitalised investors.
Headquartered in London, Biotech Capital is led by a team of Europe's leading analysts and journalists, publishing daily content, covering all key movements in the Biotechnology market.